Eupraxia Pharmaceuticals Inc. (EPRX): R&D Expense
$21.33M
Year ended 2025-12-31
+16.1%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.33M | +32.7% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $16.08M | -21.0% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $20.36M | +49.4% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $13.63M | n/a | 2024-04-01, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $21.33M | +32.7% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare EPRX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗